The prevalence of comorbidity in the lung cancer screening population: A systematic review and meta-analysis.
Anas AlmatrafiOwen ThomasMatthew CallisterRhian GabeRebecca J BeekenRichard NealPublished in: Journal of medical screening (2022)
Comorbidities were highly prevalent in LCS populations and likely to be more prevalent than in other cancer screening programmes. Further research on the burden of comorbid disease and its impact on screening uptake and outcomes is needed. Identifying individuals with frailty and comorbidities who might not benefit from screening should become a priority in LCS research.
Keyphrases